Outcome of 125 Children with Chronic Myelogenous Leukemia Who Received Transplants from Unrelated Donors

The Japan Marrow Donor Program

Hideki Muramatsu, Seiji Kojima, Ayami Yoshimi, Yoshiko Atsuta, Koji Kato, Yoshihisa Nagatoshi, Masami Inoue, Kazutoshi Koike, Takakazu Kawase, Masaki Ito, Hidemitsu Kurosawa, Akihiko Tanizawa, Chikako Tono, Kazuko Hamamoto, Noriko Hotta, Akihiro Watanabe, Yasuo Morishima, Keisei Kawa, Hiroyuki Shimada

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Because of a small number of patients, only a few studies have addressed the outcome of bone marrow transplantation (BMT) in children with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML), who receive graft from a volunteer-unrelated donor (VUD), especially after practical application of imatinib mesylate. The outcomes of BMT from a VUD in 125 children with Ph+ CML were retrospectively reviewed. Patients were identified through the Japan Marrow Donor Program as having undergone BMT between 1993 and 2005 and were aged 1-19 years at the time of transplant (median age, 14 years). The probabilities of 5-year overall survival (OS) and leukemia-free survival (LFS) were 59.3% and 55.5%, respectively. Multivariate analysis identified the following unfavorable survival factors: infused total nucleated cell dose < 314 × 106 /kg (relative risk [RR] = 2.43; 95% confidence interval [CI] = 1.33-4.44; P = .004), advanced phase (RR = 2.43; 95% CI = 1.37-4.31; P = .004), and no major cytogenetic response (MCyR) at the time of BMT (RR = 6.55; 95% CI = 1.98-21.6; P = .002). Of the 17 patients treated with imatinib, 15 (88%) achieved MCyR at the time of BMT, and this group had an excellent 5-year OS of 81.9%. Disease phase, infused total nucleated cell dose, and cytogenetic response were independent risk factors for survival of unrelated BMT. These findings provide important information for assessing the indications for and improving outcome in unrelated BMT for the treatment of pediatric CML.

Original languageEnglish
Pages (from-to)231-238
Number of pages8
JournalBiology of Blood and Marrow Transplantation
Volume16
Issue number2
DOIs
Publication statusPublished - 2010 Feb

Fingerprint

Unrelated Donors
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Bone Marrow Transplantation
Japan
Bone Marrow
Tissue Donors
Transplants
Survival
Cytogenetics
Confidence Intervals
Volunteers
Philadelphia Chromosome
Leukemia
Multivariate Analysis
Pediatrics

Keywords

  • Bone marrow transplantation
  • Children
  • Chronic myelogenous leukemia
  • Japan Marrow Donor Program
  • Stem cell transplantation
  • Unrelated donor

ASJC Scopus subject areas

  • Transplantation
  • Hematology

Cite this

Outcome of 125 Children with Chronic Myelogenous Leukemia Who Received Transplants from Unrelated Donors : The Japan Marrow Donor Program. / Muramatsu, Hideki; Kojima, Seiji; Yoshimi, Ayami; Atsuta, Yoshiko; Kato, Koji; Nagatoshi, Yoshihisa; Inoue, Masami; Koike, Kazutoshi; Kawase, Takakazu; Ito, Masaki; Kurosawa, Hidemitsu; Tanizawa, Akihiko; Tono, Chikako; Hamamoto, Kazuko; Hotta, Noriko; Watanabe, Akihiro; Morishima, Yasuo; Kawa, Keisei; Shimada, Hiroyuki.

In: Biology of Blood and Marrow Transplantation, Vol. 16, No. 2, 02.2010, p. 231-238.

Research output: Contribution to journalArticle

Muramatsu, H, Kojima, S, Yoshimi, A, Atsuta, Y, Kato, K, Nagatoshi, Y, Inoue, M, Koike, K, Kawase, T, Ito, M, Kurosawa, H, Tanizawa, A, Tono, C, Hamamoto, K, Hotta, N, Watanabe, A, Morishima, Y, Kawa, K & Shimada, H 2010, 'Outcome of 125 Children with Chronic Myelogenous Leukemia Who Received Transplants from Unrelated Donors: The Japan Marrow Donor Program', Biology of Blood and Marrow Transplantation, vol. 16, no. 2, pp. 231-238. https://doi.org/10.1016/j.bbmt.2009.09.022
Muramatsu, Hideki ; Kojima, Seiji ; Yoshimi, Ayami ; Atsuta, Yoshiko ; Kato, Koji ; Nagatoshi, Yoshihisa ; Inoue, Masami ; Koike, Kazutoshi ; Kawase, Takakazu ; Ito, Masaki ; Kurosawa, Hidemitsu ; Tanizawa, Akihiko ; Tono, Chikako ; Hamamoto, Kazuko ; Hotta, Noriko ; Watanabe, Akihiro ; Morishima, Yasuo ; Kawa, Keisei ; Shimada, Hiroyuki. / Outcome of 125 Children with Chronic Myelogenous Leukemia Who Received Transplants from Unrelated Donors : The Japan Marrow Donor Program. In: Biology of Blood and Marrow Transplantation. 2010 ; Vol. 16, No. 2. pp. 231-238.
@article{4d925cb7dee148219b69d12dc597998f,
title = "Outcome of 125 Children with Chronic Myelogenous Leukemia Who Received Transplants from Unrelated Donors: The Japan Marrow Donor Program",
abstract = "Because of a small number of patients, only a few studies have addressed the outcome of bone marrow transplantation (BMT) in children with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML), who receive graft from a volunteer-unrelated donor (VUD), especially after practical application of imatinib mesylate. The outcomes of BMT from a VUD in 125 children with Ph+ CML were retrospectively reviewed. Patients were identified through the Japan Marrow Donor Program as having undergone BMT between 1993 and 2005 and were aged 1-19 years at the time of transplant (median age, 14 years). The probabilities of 5-year overall survival (OS) and leukemia-free survival (LFS) were 59.3{\%} and 55.5{\%}, respectively. Multivariate analysis identified the following unfavorable survival factors: infused total nucleated cell dose < 314 × 106 /kg (relative risk [RR] = 2.43; 95{\%} confidence interval [CI] = 1.33-4.44; P = .004), advanced phase (RR = 2.43; 95{\%} CI = 1.37-4.31; P = .004), and no major cytogenetic response (MCyR) at the time of BMT (RR = 6.55; 95{\%} CI = 1.98-21.6; P = .002). Of the 17 patients treated with imatinib, 15 (88{\%}) achieved MCyR at the time of BMT, and this group had an excellent 5-year OS of 81.9{\%}. Disease phase, infused total nucleated cell dose, and cytogenetic response were independent risk factors for survival of unrelated BMT. These findings provide important information for assessing the indications for and improving outcome in unrelated BMT for the treatment of pediatric CML.",
keywords = "Bone marrow transplantation, Children, Chronic myelogenous leukemia, Japan Marrow Donor Program, Stem cell transplantation, Unrelated donor",
author = "Hideki Muramatsu and Seiji Kojima and Ayami Yoshimi and Yoshiko Atsuta and Koji Kato and Yoshihisa Nagatoshi and Masami Inoue and Kazutoshi Koike and Takakazu Kawase and Masaki Ito and Hidemitsu Kurosawa and Akihiko Tanizawa and Chikako Tono and Kazuko Hamamoto and Noriko Hotta and Akihiro Watanabe and Yasuo Morishima and Keisei Kawa and Hiroyuki Shimada",
year = "2010",
month = "2",
doi = "10.1016/j.bbmt.2009.09.022",
language = "English",
volume = "16",
pages = "231--238",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Outcome of 125 Children with Chronic Myelogenous Leukemia Who Received Transplants from Unrelated Donors

T2 - The Japan Marrow Donor Program

AU - Muramatsu, Hideki

AU - Kojima, Seiji

AU - Yoshimi, Ayami

AU - Atsuta, Yoshiko

AU - Kato, Koji

AU - Nagatoshi, Yoshihisa

AU - Inoue, Masami

AU - Koike, Kazutoshi

AU - Kawase, Takakazu

AU - Ito, Masaki

AU - Kurosawa, Hidemitsu

AU - Tanizawa, Akihiko

AU - Tono, Chikako

AU - Hamamoto, Kazuko

AU - Hotta, Noriko

AU - Watanabe, Akihiro

AU - Morishima, Yasuo

AU - Kawa, Keisei

AU - Shimada, Hiroyuki

PY - 2010/2

Y1 - 2010/2

N2 - Because of a small number of patients, only a few studies have addressed the outcome of bone marrow transplantation (BMT) in children with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML), who receive graft from a volunteer-unrelated donor (VUD), especially after practical application of imatinib mesylate. The outcomes of BMT from a VUD in 125 children with Ph+ CML were retrospectively reviewed. Patients were identified through the Japan Marrow Donor Program as having undergone BMT between 1993 and 2005 and were aged 1-19 years at the time of transplant (median age, 14 years). The probabilities of 5-year overall survival (OS) and leukemia-free survival (LFS) were 59.3% and 55.5%, respectively. Multivariate analysis identified the following unfavorable survival factors: infused total nucleated cell dose < 314 × 106 /kg (relative risk [RR] = 2.43; 95% confidence interval [CI] = 1.33-4.44; P = .004), advanced phase (RR = 2.43; 95% CI = 1.37-4.31; P = .004), and no major cytogenetic response (MCyR) at the time of BMT (RR = 6.55; 95% CI = 1.98-21.6; P = .002). Of the 17 patients treated with imatinib, 15 (88%) achieved MCyR at the time of BMT, and this group had an excellent 5-year OS of 81.9%. Disease phase, infused total nucleated cell dose, and cytogenetic response were independent risk factors for survival of unrelated BMT. These findings provide important information for assessing the indications for and improving outcome in unrelated BMT for the treatment of pediatric CML.

AB - Because of a small number of patients, only a few studies have addressed the outcome of bone marrow transplantation (BMT) in children with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML), who receive graft from a volunteer-unrelated donor (VUD), especially after practical application of imatinib mesylate. The outcomes of BMT from a VUD in 125 children with Ph+ CML were retrospectively reviewed. Patients were identified through the Japan Marrow Donor Program as having undergone BMT between 1993 and 2005 and were aged 1-19 years at the time of transplant (median age, 14 years). The probabilities of 5-year overall survival (OS) and leukemia-free survival (LFS) were 59.3% and 55.5%, respectively. Multivariate analysis identified the following unfavorable survival factors: infused total nucleated cell dose < 314 × 106 /kg (relative risk [RR] = 2.43; 95% confidence interval [CI] = 1.33-4.44; P = .004), advanced phase (RR = 2.43; 95% CI = 1.37-4.31; P = .004), and no major cytogenetic response (MCyR) at the time of BMT (RR = 6.55; 95% CI = 1.98-21.6; P = .002). Of the 17 patients treated with imatinib, 15 (88%) achieved MCyR at the time of BMT, and this group had an excellent 5-year OS of 81.9%. Disease phase, infused total nucleated cell dose, and cytogenetic response were independent risk factors for survival of unrelated BMT. These findings provide important information for assessing the indications for and improving outcome in unrelated BMT for the treatment of pediatric CML.

KW - Bone marrow transplantation

KW - Children

KW - Chronic myelogenous leukemia

KW - Japan Marrow Donor Program

KW - Stem cell transplantation

KW - Unrelated donor

UR - http://www.scopus.com/inward/record.url?scp=75149193809&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=75149193809&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2009.09.022

DO - 10.1016/j.bbmt.2009.09.022

M3 - Article

VL - 16

SP - 231

EP - 238

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 2

ER -